101080-38-0

Basic information

• Product Name: (2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE
• Synonyms: Acetamide,N-(2-bromophenyl)-2-(hydroxyimino)-
• CAS NO: 101080-38-0
• Molecular Formula: C₈H₇BrN₂O₂
• Molecular Weight: 243.06
• Mol File: 101080-38-0.mol

Chemical Properties

• Melting Point: 174-175 °C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.62g/cm³
• Refractive Index: 1.616
• PKA: 8.59±0.10(Predicted)
• CAS DataBase Reference: (2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(101080-38-0)
• EPA Substance Registry System: (2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE(101080-38-0)

Safety Data

• Hazardous Substances Data: 101080-38-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
(2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE is used as a research chemical for exploring its unique structure and properties. Its presence of a bromine atom and a hydroxy imino group attached to a phenyl ring allows for investigation into its reactivity and potential applications in chemical synthesis.
Used in Pharmaceutical and Medicinal Chemistry:
(2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its unique structure may confer potential biological activities, making it a candidate for drug discovery and development processes.
Used in Chemical Reactions and Synthesis Processes:
(2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE is used as a reactant in various chemical reactions due to its distinctive functional groups. Its versatility in forming different types of chemical bonds and its potential to participate in a range of synthesis processes make it a valuable component in the creation of new compounds and materials.
Used in Material Science:
(2E)-N-(2-BROMOPHENYL)-2-(HYDROXYIMINO)ACETAMIDE may be utilized in the development of new materials, given its potential to influence the properties of polymers and other materials through its chemical interactions. Its bromine atom and hydroxy imino group could contribute to the creation of materials with specific characteristics for various applications.

InChI:InChI=1/C8H7BrN2O2/c9-6-3-1-2-4-7(6)11-8(12)5-10-13/h1-5,13H,(H,11,12)/b10-5-

Upstream product

• 302-17-0 chloral hydrate 
• 615-36-1 2-bromoaniline 
• 94718-79-3 o-bromoaniline hydrochloride 
• 349637-17-8 C₈H₅BrCl₃NO 
• 515-83-3 chloral ethyl hemiacetal 
• 75-87-6 chloral 

Downstream Products

• 1332882-48-0 C₁₅H₉BrFN₃O₂ 
• 1332882-49-1 C₁₅H₉BrFN₃O₂ 
• 1374203-76-5 4-(3-{4-[8-(6-fluoro-pyridin-3-yl)-4-morpholin-4-yl-quinazolin-2-yl]-phenyl}-ureido)-N,N-dimethyl-benzamide 
• 1374203-75-4 4-(3-{4-[8-(3-hydroxy-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-phenyl}-ureido)-N,N-dimethyl-benzamide 
• 40619-69-0 2-(7-bromo-1H-indole-3-yl)ethylamine 
• 115666-21-2 7-bromo-1 H-indole-3-carbaldehyde 
• 51417-51-7 7-bromo-1H-indole 
• 20780-74-9 7-bromoisatin 
• 91-56-5 indole-2,3-dione 
• 1469872-18-1 2-(7-bromo-2,3-dioxoindolin-1-yl)-N-phenylacetamide 
• 1421695-55-7 C₁₇H₁₂BrNO₄S 
• 1421695-54-6 C₁₄H₇BrN₂O₄S 
• 1336960-23-6 3-(1,4'-bipiperidin-1'-ylmethyl)-8-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide 
• 1336964-51-2 3-(1,4'-bipiperidin-1'-ylmethyl)-8-bromo-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxylic acid 

Relevant articles and documents

Synthesis and kinase inhibitory activity of novel substituted indigoids

The bis-indole indigoids are a promising protein kinase inhibitor scaffold to be further evaluated against the numerous human diseases that imply abnormal regulation of kinases including neurodegenerative disorders. In an effort to identify new pharmacolo

Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases

DYRK kinases are involved in alternative pre-mRNA splicing as well as in neuropathological states such as Alzheimer's disease and Down syndrome. In this study, we present the design, synthesis, and biological evaluation of indirubins as DYRK inhibitors wi

Methylisoindigo and its bromo-derivatives are selective tyrosine kinase inhibitors, repressing cellular stat3 activity, and target CD133+ cancer stem cells in PDAC

Indirubin is an active component of the herbal ingredient 'Danggui Longhui wan', which was used for the treatment of inflammation and chronic myeloid leukemia in China. The recent study showed its derivative methylisoindigo (also known as meisoindigo) preferentially targeting cancer stem cells (CSCs) in interference with AMPK and LKB1, the cellular metabolic sensors. In this study, we screened the effect of meisoindigo on a panel of 300 protein kinases and found that it selectively inhibited Stat3-associated tyrosine kinases and further confirmed its activity in cell based assays. To gain a deeper insight into the structure-activity relationship we produced 7 bromo-derivatives exhausting the accessible positions on the bisindole backbone except for in the 4-position due to the space limitation. We compared their anti-proliferative effects on tumor cells. We found that 6-bromomeisoindigo showed improved toxicity in company with increased Stat3 inhibition. Moreover, we detected that 6-bromomeisoindigo induced apoptosis of 95% of CD133+ pancreatic cancer cells. Considering that CD133 is a common marker highly expressed in a range of CSCs, our results imply the potential application of 6-bromomeisoindigo for the treatment of CSCs in different types of cancers.

A 1 - (phenyl) - 2, 3, 4, 9-tetrahydro -1H-pyrido [3,4-b] indole derivatives thereof in the preparation of the application of the anti-tumor drug (by machine translation)

The invention belongs to the technical field of pharmaceutical chemistry, in particular to a kind of 1 - (phenyl) - 2, 3, 4, 9-tetrahydro -1H-pyrido [3,4-b] indole derivatives thereof in the preparation of the application of the anti-tumor drugs. Research display inhibit one or more prostandin receptor activity can be effective for the treatment of hypertension, at least one kind of prostagladin E2 receptor in the blood pressure regulating system RAAS in the course of play a crucial role, we by changing 1 and 8 is the angle of the two groups and the distance to EP3 receptor research, we developed a new high-efficiency of the synthetic route to study a series of derivatives, all of the target compound are all new product, all of the compound through the nuclear magnetic resonance and quality of the identification of the structure. The target compound in the antibacterial, anti-tumor, analgesic, anti-platelet aggregation, the promotion of kidney part of the reabsorption of sodium and water, regulating neurotransmitter release, promote adipose tissue Lipolysis and has an important role of anti-arrhythmia. (by machine translation)

Synthesis of 7-halo indoles (by machine translation)

The present invention relates to synthesis of 7? Halo indole method, comprising the steps of:O-halogenated aniline, chloral hydrate and hydroxylamine hydrochloride by the Sandmeyer reaction to synthesize 7? halogenating isatin ; 7? halogenating isatin dissolved with an organic solvent, in the reducing agent by reduction reaction under the conditions of 7? Halo indole, the reducing agent is an alkali metal borohydride system, four system adopts, lithium hydride system or triethyl silane system. The beneficial effect of the invention is:in order to O-halogenated aniline and the chloral hydrate is, hydroxylamine hydrochloride as raw materials, by the Sandmeyer shall synthesis method for preparing compositions b isonitroso 7? halogenating isatin, and then by further reduction and system reduction to prepare 7? Halo indole; by the 7? Preparation halogenating isatin 7? Halo indole method, the raw material is easy to obtain, low price, higher process yield, the product purity is good, simple operation, and the like, is suitable for batch preparation 7? Halo indole. (by machine translation)

Structure-based design, synthesis, andanticonvulsant activity of isatin-1-N-phenylacetamide derivatives

In an effort to develop the potent anticonvulsant agents, a series of novel isatin-1-N-phenylacetamide derivatives was synthesized and screened for their in vivo anticonvulsant activity against maximal electroshock test and evaluated for their neurotoxicity by the rotarod test at the same dose levels. Ten compounds exhibited the anticonvulsant activity. 2-(5-Methyl-2,3-dioxoindolin-1- yl)-N-phenylacetamide (4b) was found to be the most potent compound of the series with an ED50 of 91.3 mg/kg, TD50 of >1,000 mg/kg, a higher protective index (PI = TD50/ED50, >11) was gained than the reference drug phenobarbital and carbamazepine. The essential structural features responsible for interaction with receptor site are established within a suggested pharmacophore. Springer Science+Business Media 2013.

Synthesis and evaluation of novel sulfenamides as novel anti Methicillin-resistant Staphylococcus aureus agents

A total of 29 novel sulfenamide compounds were synthesized, spectroscopically characterized and evaluated in vitro for antimicrobial activity against various infectious pathogens. Compounds 1b and 2c exhibited potent inhibition against clinical Methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentration (MIC) values of 1.56 μg/mL.

Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2- diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives

To further expand the structure-cytotoxic activity relationships of isatin derivatives and to reduce flexibility in substituent groups at nitrogen, 20 analogues incorporating a ring system between the N1 and C7 atoms of isatin were prepared using a variety of synthetic strategies. This yielded pyrroloindole-, pyrroloquinoline-, pyrroloacridine-, pyrrolophenanthridine- and benzopyrrolophenanthridine-based systems with embedded isatin moieties, the latter possessing a novel carbon skeleton. These compounds were subsequently assessed for their in vitro cytotoxicity against human U937 lymphoma cells, with the brominated pyrroloacridine dione 27 showing the most promising activity (IC50 3.01 μM) after 24 h.

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

TRPV4 ANTAGONISTS

The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.